TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10987525

Group type: EXPERIMENTAL
Intervention: Nerve conduction velocity test
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Pressure‐Specified Sensory Device
Number of subjects: 79
Study: 9202963

Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Diclofenac sodium eye drops
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 39
Study: 8307772

Group type: EXPERIMENTAL
Intervention: Video with information and skills training (experimental)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Video with information only (control)
Number of subjects: 69
Study: 2886821

Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 565

Group type: COMPARATOR
Intervention: Cyclophosphamide and cisplatin (CP)
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin, and cisplatin (CAP)
Number of subjects: 565
Study: 30535269

Group type: EXPERIMENTAL
Intervention: Intensive counseling program (seven telephone sessions)
Number of subjects: 1604

Group type: COMPARATOR
Intervention: Quitline referral (1-2 telephone counseling sessions)
Number of subjects: 1604
Study: 29290126

Group type: EXPERIMENTAL
Intervention: Promotora intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Promotora and video interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (nonintervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group video sessions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual video sessions with video and promotora
Number of subjects: 0
Study: 29030329

Group type: EXPERIMENTAL
Intervention: Access to the colorectal cancer module of the German DIPEx website for 2 weeks
Number of subjects: 212

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 212
Study: 23919667

Group type: EXPERIMENTAL
Intervention: Transforming methacrylate dressing (TMD)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Silver-containing carboxymethylcellulose dressing (CMC-Ag)
Number of subjects: 19
Study: 23927320

Group type: EXPERIMENTAL
Intervention: DCE-CT QA protocol with dynamic flow imaging phantom
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: ASIR reconstruction process
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Vendor specific modes (e.g., axial shuttle)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: DCE-CT QA protocol
Number of subjects: 3
Study: 21529740

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg 12 hours before intervention with another 40 mg preprocedure dose, n = 120)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg 12 hours before intervention with another 40 mg preprocedure dose)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo (n = 121)
Number of subjects: 241
Study: 18971603

Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform (Bi), energies used: 100-150-200-300-360 J
Number of subjects: 224

Group type: COMPARATOR
Intervention: Monophasic shock waveform (Mo), energies used: 100-200-300-360 J
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Both groups (Bi and Mo)
Number of subjects: 224
Study: 16522927

Group type: EXPERIMENTAL
Intervention: Experimental partially hydrolyzed rice protein-based formula (RPF)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard intact cow's milk protein-based formula (CMF)
Number of subjects: 65
Study: 12975676

Group type: EXPERIMENTAL
Intervention: Occupational therapy (OT) combined with clozapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clozapine alone
Number of subjects: 0
Study: 10755397

Group type: EXPERIMENTAL
Intervention: MPH‐P treatment administered just after diagnosis (4 days every 6 weeks)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Treatment at disease progression
Number of subjects: 145

Group type: COMPARATOR
Intervention: Patients treated at disease progression
Number of subjects: 145
Study: 8874688

Group type: EXPERIMENTAL
Intervention: Physician nutrition counseling training plus a structured office practice environment for nutrition management (prompts and the provision of lipid results and counseling algorithms)
Number of subjects: 1278

Group type: EXPERIMENTAL
Intervention: Physician nutrition counseling training
Number of subjects: 1278

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1278
Study: 1608258

Group type: EXPERIMENTAL
Intervention: Selective Auditory Attention Test (SAAT)
Number of subjects: 40
Study: 6366100

Group type: EXPERIMENTAL
Intervention: O-(beta-hydroxyethyl)-rutosides (HR) 2 g/day
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 30072263

Group type: EXPERIMENTAL
Intervention: Antithrombin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29885165

Group type: EXPERIMENTAL
Intervention: Peri-tubal local anaesthetic infiltration of 0.25% bupivacaine
Number of subjects: 68

Group type: COMPARATOR
Intervention: 10ml 0.9% normal saline infiltration
Number of subjects: 68
Study: 28325013

Group type: EXPERIMENTAL
Intervention: Mirror therapy combined with Electrical Stimulation (ES)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 18
Study: 25219290

Group type: EXPERIMENTAL
Intervention: Neutrophil-to-lymphocyte ratio (NLR) in patients with peripheral vertigo
Number of subjects: 103

Group type: COMPARATOR
Intervention: Neutrophil-to-lymphocyte ratio (NLR) in healthy controls
Number of subjects: 103
Study: 22507360

Group type: EXPERIMENTAL
Intervention: High-risk intervention using psychologically informed practice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening and targeted approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current best practice
Number of subjects: 0
Study: 20211180

Group type: EXPERIMENTAL
Intervention: Prolonged low-dose peginterferon-alpha2a therapy and beta-blockers
Number of subjects: 598
Study: 18174491

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 8832
Study: 16149365

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 28
Study: 11880102

Group type: EXPERIMENTAL
Intervention: Urokinase gene 3'-UTR T/C polymorphism
Number of subjects: 153

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 153
Study: 10520842

Group type: EXPERIMENTAL
Intervention: Intravenous hyoscyamine (0.25 mg)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Oral hyoscyamine (0.25 mg)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 7741341

Group type: EXPERIMENTAL
Intervention: Ethanol (1.1 gm/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (equal volume of water added to nonalcoholic beer)
Number of subjects: 20
Study: 2037704

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 16
Study: 6290927

Group type: EXPERIMENTAL
Intervention: ACTH4-9 Analogue (ORG 2766)
Number of subjects: 4
Study: 31839558

Group type: EXPERIMENTAL
Intervention: CPAP treatment plus usual care (CPAP group)
Number of subjects: 2551

Group type: COMPARATOR
Intervention: Usual care alone (UC group)
Number of subjects: 2551

Group type: COMPARATOR
Intervention: Reference group (no OSA)
Number of subjects: 2551
Study: 31409522

Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 521

Group type: COMPARATOR
Intervention: GnRH agonist
Number of subjects: 521
Study: 28701501

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment (systolic BP <140 mm Hg)
Number of subjects: 989

Group type: COMPARATOR
Intervention: Standard blood pressure treatment (systolic BP <180 mm Hg)
Number of subjects: 989

Group type: EXPERIMENTAL
Intervention: NCCT markers (intrahematoma hypodensities, black hole sign, swirl sign, blend sign, heterogeneous hematoma density, irregular shape)
Number of subjects: 989
Study: 25526517

Group type: EXPERIMENTAL
Intervention: HDHK program (7 sessions)
Number of subjects: 122
Study: 24420550

Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 21182510

Group type: EXPERIMENTAL
Intervention: Zinc pyrithione (ZPT) shampoo, treated for 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-medicated product, treated for 3 weeks
Number of subjects: 0
Study: 19610263

Group type: EXPERIMENTAL
Intervention: Emollient cream with furfuryl palmitate
Number of subjects: 117

Group type: COMPARATOR
Intervention: Basic emollient cream
Number of subjects: 117
Study: 17563160

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Continuation‐phase cognitive therapy
Number of subjects: 156
Study: 15964328

Group type: EXPERIMENTAL
Intervention: Combined spinal and epidural anesthesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 50
Study: 11847621

Group type: EXPERIMENTAL
Intervention: PCL-substituting TKA
Number of subjects: 47

Group type: COMPARATOR
Intervention: PCL-retaining TKA
Number of subjects: 47
Study: 10076915

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 0
Study: 8963853

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.5% before and after ALT
Number of subjects: 471

Group type: COMPARATOR
Intervention: Brimonidine 0.5% before ALT and vehicle after
Number of subjects: 471

Group type: COMPARATOR
Intervention: Vehicle before and brimonidine 0.5% after
Number of subjects: 471

Group type: COMPARATOR
Intervention: Vehicle before and after ALT
Number of subjects: 471
Study: 2301911

Group type: EXPERIMENTAL
Intervention: Caudal bupivacaine block
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bupivacaine wound instillation
Number of subjects: 50
Study: 6766244

Group type: EXPERIMENTAL
Intervention: Ceruletide
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 31289062

Group type: EXPERIMENTAL
Intervention: Pleasure&Pregnancy programme (web-based interactive educational programme) for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expectant management (EM) for 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pleasure&Pregnancy programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expectant management (EM)
Number of subjects: 0
Study: 28430722

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine and bupivacaine injection
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (normal saline injection)
Number of subjects: 76
Study: 26010427

Group type: EXPERIMENTAL
Intervention: Standard doses of peginterferon α-2b plus low and escalating doses of ribavirin (group 1)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low doses of peginterferon α-2b plus low and escalating doses of ribavirin (group 2)
Number of subjects: 32
Study: 23700328

Group type: EXPERIMENTAL
Intervention: Slackline training (5 times per week for 10 minutes over 6 weeks)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Slackline training
Number of subjects: 34
Study: 22111518

Group type: COMPARATOR
Intervention: Aerobic exercise (AER; running)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Resistance exercise (RES; free and machine weights)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 10
Study: 19471031

Group type: EXPERIMENTAL
Intervention: Telesonography
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control (ordinary ultrasound referral)
Number of subjects: 108
Study: 17576587

Group type: EXPERIMENTAL
Intervention: Communication skills training program
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 32
Study: 12697600

Group type: EXPERIMENTAL
Intervention: Forced air warming (set to 'medium')
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Carbon-fibre resistive warming (38 degrees C)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Circulating water mattress (38 degrees C)
Number of subjects: 24
Study: 10715306

Group type: EXPERIMENTAL
Intervention: Capecitabine 1,331 mg/m²/d bid continuously (arm A)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Capecitabine 2,510 mg/m²/d bid intermittently (2 weeks on/1 week off) (arm B)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Capecitabine 1,657 mg/m²/d plus oral leucovorin 60 mg/d bid intermittently (2 weeks on/1 week off) (arm C)
Number of subjects: 109
Study: 9374948

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 20 mg once daily
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 1304283

Group type: EXPERIMENTAL
Intervention: Iopanoic acid (500 mg orally twice a day for the first 3 weeks) and carbimazole (30 mg orally in three divided doses)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Carbimazole alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Iopanoic acid and carbimazole
Number of subjects: 30
Study: 2932908

Group type: EXPERIMENTAL
Intervention: Fluorouracil (FU) + Hydroxyurea (HU)
Number of subjects: 64

Group type: COMPARATOR
Intervention: MOF-Strep (methyl-CCNU, oncovin, fluorouracil, and streptozotocin)
Number of subjects: 64
Study: 31672939

Group type: EXPERIMENTAL
Intervention: High-salt diet
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low-salt diet
Number of subjects: 11
Study: 30218416

Group type: EXPERIMENTAL
Intervention: L-praziquantel (PZQ) administered in two new oral dispersion tablet (ODT) formulations under various combinations of co-administration with food, water, and/or crushing.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model for AUC extrapolated to children 2-5 years old accounting for enzyme maturation and weight.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Model used for healthy adult volunteers.
Number of subjects: 0
Study: 30645842

Group type: EXPERIMENTAL
Intervention: Penning Granule (PG), 105 g each time, twice per day for 4 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Levofloxacin (0.5 g, once per day) and Metronidazole Tablet (0.5 g, twice daily for 1 week)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Penning Granule (PG)
Number of subjects: 38
Study: 25047312

Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam (0.3 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous midazolam (0.15 mg/kg)
Number of subjects: 60
Study: 22496436

Group type: EXPERIMENTAL
Intervention: Multifocal rotationally asymmetric Lentis Mplus LS‐312 IOL with capsular tension ring
Number of subjects: 90

Group type: COMPARATOR
Intervention: Multifocal rotationally asymmetric Lentis Mplus LS‐312 IOL without capsular tension ring
Number of subjects: 90
Study: 20508466

Group type: EXPERIMENTAL
Intervention: weight+EMS (ES)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: weight (VOL)
Number of subjects: 28

Group type: COMPARATOR
Intervention: control group (CG)
Number of subjects: 28
Study: 18226581

Group type: COMPARATOR
Intervention: Six cycles of CHOP-14
Number of subjects: 1222

Group type: COMPARATOR
Intervention: Eight cycles of CHOP-14
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Six cycles of R-CHOP-14
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Eight cycles of R-CHOP-14
Number of subjects: 1222
Study: 15976214

Group type: EXPERIMENTAL
Intervention: Music (music group; n = 28)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No music (control group; n = 26)
Number of subjects: 54
Study: 12583944

Group type: EXPERIMENTAL
Intervention: Intermittent chemotherapy (break in chemotherapy, re-starting on the same drug on progression)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Continuous chemotherapy (until progression)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 354
Study: 10224577

Group type: EXPERIMENTAL
Intervention: Streptokinase-mediated fibrinolysis (group I, n = 8)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous heparin by infusion (group II, n = 12)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fibrinolysis after unsuccessful heparin treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Heparin treatment (unsuccessful case)
Number of subjects: 20
Study: 8673811

Group type: EXPERIMENTAL
Intervention: Borrelia burgdorferi antigens
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Salmonella antigens
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Shigella antigens
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Yersinia antigens
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy blood donors)
Number of subjects: 30
Study: 1899455

Group type: EXPERIMENTAL
Intervention: Average dialysis treatment duration of less than 3.5 hours
Number of subjects: 600

Group type: COMPARATOR
Intervention: Average dialysis treatment duration longer than 3.5 hours
Number of subjects: 600
Study: 6848412

Group type: EXPERIMENTAL
Intervention: Indium 111 leukocyte scan
Number of subjects: 15

Group type: COMPARATOR
Intervention: Barium enema, colonoscopy, or surgery (control)
Number of subjects: 15
Study: 31262599

Group type: EXPERIMENTAL
Intervention: High intra-abdominal pressure (IAP) during HIPEC (19 mmHg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Low intra-abdominal pressure (IAP) during HIPEC (11 mmHg)
Number of subjects: 38
Study: 29415906

Group type: EXPERIMENTAL
Intervention: NKCP® (250 mg daily for 4 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 27112031

Group type: EXPERIMENTAL
Intervention: Percutaneous radio-frequency ablation with ethanol injection (2.5-9.6 mL) and temperature control at 45-56 °C for more than 10 min.
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (ablation without ethanol injection, lesions more than 5 mm from gastrointestinal tract).
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Study group (percutaneous radio-frequency ablation).
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (percutaneous radio-frequency ablation).
Number of subjects: 141

Group type: COMPARATOR
Intervention: Both groups (study and control).
Number of subjects: 141
Study: 23823459

Group type: EXPERIMENTAL
Intervention: Foot self-care educational intervention (3 sessions over 3 weeks)
Number of subjects: 70
Study: 22452487

Group type: EXPERIMENTAL
Intervention: UVA and UVB exposure
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Energy skin phototypes (ESPTs) classification
Number of subjects: 31
Study: 20445356

Group type: EXPERIMENTAL
Intervention: Ski helmet
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ski cap
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bareheaded
Number of subjects: 30
Study: 18536337

Group type: EXPERIMENTAL
Intervention: Exercise intervention (90 min duration, 8 times over 3 months) including flexibility, resistance, and movement exercises.
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 88
Study: 16047027

Group type: EXPERIMENTAL
Intervention: Arginine supplementation (15 g/day for 4 weeks after pneumococcal vaccine)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (only the vaccine)
Number of subjects: 29
Study: 12374442

Group type: EXPERIMENTAL
Intervention: Threat primes (subliminal threat)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral-word primes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attachment anxiety
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attachment avoidance with threat prime 'separation'
Number of subjects: 0
Study: 9915512

Group type: EXPERIMENTAL
Intervention: Automatic long‐throw guns (Acecut, Asap, Biopty, Magnum)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional type side‐notch needle (Trucut), aspiration needle (Surecut), end‐cut needle (Autovac)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Short‐throw Monopty gun
Number of subjects: 44
Study: 7479215

Group type: EXPERIMENTAL
Intervention: Haemodialysis
Number of subjects: 66

Group type: COMPARATOR
Intervention: Non-dialysis treatment
Number of subjects: 66

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 66
Study: 2209300

Group type: EXPERIMENTAL
Intervention: Heavy-resistance weight training 3 days/wk for 10 wk
Number of subjects: 8
Study: 6994939

Group type: EXPERIMENTAL
Intervention: Diphenylhydantoin (DPH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diphenylhydantoin (DPH) cessation
Number of subjects: 0
Study: 31305297

Group type: EXPERIMENTAL
Intervention: Apatinib
Number of subjects: 45
Study: 28297049

Group type: EXPERIMENTAL
Intervention: Liposomal prednisolone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 25934853

Group type: EXPERIMENTAL
Intervention: Etanercept (50 mg, subcutaneous, once weekly for 24 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (identical to etanercept)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 41

Group type: COMPARATOR
Intervention: Etanercept and Placebo
Number of subjects: 41
Study: 23636552

Group type: EXPERIMENTAL
Intervention: Low cost, home‐based physical activity and nutrition program
Number of subjects: 176
Study: 21325445

Group type: EXPERIMENTAL
Intervention: CMF followed by goserelin
Number of subjects: 1063

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 1063

Group type: COMPARATOR
Intervention: Goserelin
Number of subjects: 1063
Study: 19743725

Group type: EXPERIMENTAL
Intervention: 3-step acne system (salicylic acid cleanser 2% twice daily, salicylic acid toner 2% once daily, solubilized BPO gel 5% twice daily)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control (cleanser twice daily plus clindamycin 1%-BPO 5% gel twice daily)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 139
Study: 17407459

Group type: EXPERIMENTAL
Intervention: Early exposure to an odorant for 30 min beginning 4-37 min after birth
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Late exposure to an odorant for 30 min beginning 12 hours post-partum
Number of subjects: 55
Study: 15209304

Group type: EXPERIMENTAL
Intervention: Lyrical Music
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Instrumental Music
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Talking
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control
Number of subjects: 57
Study: 11192885

Group type: EXPERIMENTAL
Intervention: Temperature-controlled radiofrequency tissue volume reduction (RFTVR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Laser vaporizing turbinoplasty (LVT)
Number of subjects: 24